0 TSX News - October 22, 2024Enthusiast Gaming to Announce 3rd Quarter 2024 Results on November 14, 2024LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX:EGLX) will report […]Read More
0 NASDAQ Companies - October 22, 2024Verizon delivers strong third quarter results with customer growth in mobility, extending industry leadershipAchieves fixed wireless subscriber target 15 months ahead of schedule and double-digit growth in total broadband connections Company remains on […]Read More
0 TSX News - October 22, 2024Xtract One Secures Contract with Global Automotive Manufacturer to Enhance Security at Select North American FacilitiesTORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today […]Read More
0 TSX Venture News - October 22, 2024Giyani’s Demonstration Plant Commences CommissioningTORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company“), developer of the K.Hill […]Read More
0 TSX Venture News - October 22, 2024Bunker Hill Mining Provides Exploration Update Defines High-Grade Silver TargetHIGHLIGHTS: The in-progress resource conversion drill campaign totaling 8,000 feet (2,440 metres) is on track for completion to be completed […]Read More
0 TSX Venture News - October 22, 2024Inventus Mining Announces Senior Management ChangesTORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSX VENTURE: IVS) (“Inventus” or the “Company”) is pleased to […]Read More
0 NYSE Companies - October 22, 2024Interpublic Announces Third Quarter and First Nine Months 2024 ResultsNew York, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) — Total revenue including billable expenses was $2.63 billion Revenue before billable […]Read More
0 NYSE Companies - October 22, 2024Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults […]Read More